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Introduction {#sec001}
============

Antimicrobial resistance (AMR) is a critical public health issue. Antimicrobial-resistant infections can require prolonged treatments, extend hospital stays, and result in greater disability and death compared with susceptible infections \[[@pone.0216747.ref001]\]. An objective of the World Health Organization (WHO) global action plan on AMR is to strengthen the evidence base through surveillance \[[@pone.0216747.ref002]\]. Phenotypic culture-based antimicrobial susceptibility testing (AST) is routinely used, however it requires culture and lacks resistance gene information, such as mutations in chromosomal genes or the presence of mobile genetic elements which harbor AMR genes \[[@pone.0216747.ref003]--[@pone.0216747.ref005]\]; such genotypic information offers useful resolution for epidemiologic purposes, such as tracking the spread of CTX-M \[[@pone.0216747.ref006]\]. Furthermore, assays that can work in direct stool are advantageous because this specimen is readily accessible compared with those of invasive sites.

We designed and developed 85 genotypic assays primarily targeting Enterobacteriaceae since antibiotic resistance in these bacteria is a particularly threat \[[@pone.0216747.ref001], [@pone.0216747.ref007], [@pone.0216747.ref008]\]. We focused on *E*. *coli* because this was the most frequently reported bacteria in the WHO global antimicrobial resistance surveillance system (GLASS) \[[@pone.0216747.ref009]\] and has been associated with the greatest mortality and morbidity \[[@pone.0216747.ref010]\]. The assays covered 10 important antimicrobial classes used in human and veterinary medicine including penicillins, cephalosporins, carbapenems, fluoroquinolones, macrolides, aminoglycosides, polymyxins, folate pathway inhibitors, tetracyclines, and phenicols. Here we demonstrate the performance of these assays versus sequencing, compare genotypic results to phenotypic AST, and evaluate the utility of the assays on direct stool.

Materials and methods {#sec002}
=====================

Bacterial isolates {#sec003}
------------------

For validation we tested a variety of both retrospectively and prospectively collected bacterial isolates, including 201 isolates from the Food and Drug Administration and Centers for Disease Control and Prevention Antibiotic Resistance Isolate Bank (FDA-CDC AR bank, CDC, Atlanta, GA, USA), 15 isolates from Antibacterial Resistance Leadership Group (ARLG, Durham, NC, USA), and 20 isolates from American Type Culture Collection (ATCC, Manassas, VA, USA), all of which had been previously sequenced. These isolates represented a range of species, mostly from Enterobacteriaceae ([S1 Table](#pone.0216747.s001){ref-type="supplementary-material"}). The AMR gene accession numbers provided by the resources are summarized in [S2](#pone.0216747.s002){ref-type="supplementary-material"} and [S3](#pone.0216747.s003){ref-type="supplementary-material"} Tables. Additionally, we used 81 *E*. *coli* isolates from human stool from Tanzania (Haydom Lutheran Hospital, Haydom), collected as part of the Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED) birth cohort study \[[@pone.0216747.ref011]\] to yield a distribution of phenotypically resistant isolates. We also used 107 *E*. *coli* isolates from swine feces which were prospectively collected starting February 2018 for an AMR monitoring study in Thailand (Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok). This allowed us to obtain at least several resistant bacterial isolates for each antimicrobial agent.

Stool specimens {#sec004}
---------------

Two hundred and twenty direct stool specimens were used, including 70 human stool samples from Tanzania (Haydom Lutheran Hospital, Haydom) also collected as a part of the MAL-ED study. The MAL-ED study was reviewed and approved by the National Institute for Medical Research, Tanzania and the University of Virginia Institutional Review Board (IRB), and informed consent was obtained from the parents or legal guardians of all subjects. One hundred and fifty consecutive swine stool samples from Thailand (Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok) were collected in February 2018. Animal specimen collection protocol no. 013/2561 was reviewed and approved by Siriraj Animal Care and Use Committees, Siriraj Hospital, Mahidol University. For culture, stool samples were streaked on MacConkey agar and incubated at 35 ± 2°C for 18--24 hour. Five to ten suspected *E*. *coli* colonies were screened by using *E*. *coli* specific PCR assay then confirmed *E*. *coli* colonies were pooled and stored in preservative media at -70°C. Prior to AST, bacteria were subcultured on blood agar (TSA w/ 5% sheep blood, Thermo Scientific, NY, USA) at 35 ± 2°C for 18--24 hours.

DNA extraction {#sec005}
--------------

Genomic DNA from direct stool was extracted using the QIAamp Fast DNA Stool mini kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Bacterial DNA was extracted by resuspending bacterial colonies in 200 μl TE buffer (10mM Tris-HCl, 1mM EDTA, pH 7.5) or from 500 μl of 0.5 McFarland standard bacterial suspension prepared for phenotypic antimicrobial susceptibility test by centrifugation at 5000x g for 10 min, followed by resuspending the bacterial pellet with 200 μl TE buffer. The bacterial suspensions were incubated at 95°C for 15 min followed by centrifugation at 5000x g for 10 min. The supernatant was stored at -20°C to be used as DNA template.

PCR Assay development {#sec006}
---------------------

The primers for amplification of 80--150 bp products and TaqMan probes were designed using Primer Express3 (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA) and online available tool Primer3 (<http://bioinfo.ut.ee/primer3/>) or adopted from published sources ([S4 Table](#pone.0216747.s004){ref-type="supplementary-material"}). For Sanger sequencing confirmation, primers that amplified longer products (400--800 bp) were designed using primer3 (<http://bioinfo.ut.ee/primer3>) ([S5 Table](#pone.0216747.s005){ref-type="supplementary-material"}). The in silico specificity of primers and probes were tested by using Basic Local Alignment Search Tool (BLAST; <https://blast.ncbi.nlm.nih.gov/Blast.cgi>). Optimization of conditions and specificity testing of AMR-PCR assays was performed using 384 well plates on the ViiA7 platform (Applied Biosystems, Life Technologies Corporation). Each assay was amplified in duplex (see pairings in [S4 Table](#pone.0216747.s004){ref-type="supplementary-material"}). Primer/probe sets (final concentrations of 0.9 μM and 0.25 μM for primers and probes, respectively) were assayed in a 5 μl PCR mixture containing 2.5 μl of 2x PCR buffer, 0.2 μl of 25x PCR enzyme of AgPath-ID-PCR kit (Applied Biosystems, Life Technologies Corporation), 0.89 μl nuclease free water, and 1 μl of genomic DNA. Cycling conditions included an initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 1 min. The positive control sources included either well-characterized bacterial isolates or synthetic fragment/plasmid controls (Genewiz Inc., South Plainfield, NJ, USA). Synthetic positive control plasmids were constructed (Genewiz Inc.) if neither the genomic material nor the relevant bacterium was available; this included CTX-M8, CMY-1, FOX, GES, gyrA87G-*E*.*coli*, gyrA87N-Y-*Salmonella* spp., and mcr-2. A synthetic positive control plasmid was also constructed (Genewiz Inc.) to contain the primer and probe regions of all 85 targets and used as a positive control for evaluating analytical performance. Genomic DNA of *E*. *coli* ATCC 25922 was used as negative control, and nuclease-free water was used as a no-template control.

PCR assay evaluation {#sec007}
--------------------

AMR-PCR assay efficiency and linearity were first determined on the 384 well plate format and subsequently on the TaqMan array card format. For the 384 well plate, the synthetic positive control plasmids (Genewiz Inc.) which contained primer/probe regions of all targets were 10-fold serially diluted in a range of 10^7^ to 1 copy/μl then 1 μl of diluted samples was tested in each 5 μl reaction in triplicate. For the array card format, since the volume of DNA used in the array card is 5-fold lower (0.2 μl/reaction), dilutions of positive control plasmids were prepared in a range of 5x10^7^ to 5 copy/μl to ensure equivalence on both formats. Twenty microliter of each diluted sample was tested in triplicate by mixing with PCR reagents to a total 100 μl then loaded into an array card. The limit of detection (LOD) and precision (repeatability and reproducibility) were determined by spiking positive control plasmid into donor stool followed by extraction and then amplification on the array card. Repeatability was tested with eight repeats of two samples respectively spiked with a high (10^6^ copies/200 mg stool) and a low (10^4^ copies/200 mg stool) concentration of positive control plasmid. Reproducibility was tested with 10 identically spiked samples for each concentration (10^6^ and 10^4^ copies/200 mg stool were interrogated) that were extracted and assayed over 5 days. LOD was defined as the lowest concentration at which the target could be detected in all 10 spiked samples. When comparing the performance of the AMR assays against previously-sequenced bacterial isolates, any discrepancies between PCR and sequence underwent confirmatory repeat PCR and sequencing.

Evaluation of TaqMan array card {#sec008}
-------------------------------

The TaqMan array card was performed as previously described \[[@pone.0216747.ref012]\]. Briefly, primer and TaqMan probe oligonucleotides were synthesized and spotted into the microfluidic card by Applied Biosystems (Life Technologies Corporation). Twenty microliters of input DNA was mixed with 50 μl of 2x PCR buffer, 4 μl of 25x PCR enzyme of AgPath-ID-PCR kit (Applied Biosystems, Life Technologies Corporation), and 26 μl of nuclease free water to yield a 100 μl final volume. This mixture was loaded into each port of the card and the card was centrifuged twice at 1,200 rpm for 1 min and then sealed. The loading ports were excised and the full card was inserted into a ViiA7 instrument (Life Technologies Corporation) and run under the same cycling conditions as described above.

Sanger sequencing {#sec009}
-----------------

The resistance-associated genes were amplified using primers described in [S5 Table](#pone.0216747.s005){ref-type="supplementary-material"}. The PCR reaction assembly and cycling conditions were described previously \[[@pone.0216747.ref013]\]. In brief each 25 μl PCR mixture contained 12.5 μl HotStarTaq master mix (Qiagen), 0.25 μl of the 50 μM forward and reverse primers (final concentration of 0.5 μM), 7 μl nuclease free water, and 5 μl of genomic DNA. PCR was performed on a CFX96 (Bio-Rad, Hercules, CA, USA) and included an initial denaturation step at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 30 sec, with a final extension step at 72°C for 10 min. PCR products were analyzed on 2% agarose-gels and verified PCR products were purified using MinElute 96 UF PCR Purification Kit (Qiagen) following the manufacturer's protocol. The purified PCR products were measured spectrophotometrically, diluted with nuclease free water and mixed with primers then submitted to GeneWiz for DNA sequencing (Genewiz Inc.).

Phenotypic antimicrobial susceptibility testing {#sec010}
-----------------------------------------------

The repository isolates and the isolates from Thailand underwent susceptibility testing by broth microdilution method while isolates from Tanzania were previously tested by disc diffusion for ampicillin (AMP), ampicillin/sulbactam (SAM), cefazolin (CFZ), ceftazidime (CAZ), ceftriaxone (CRO), aztreonam (ATM), cefepime (FEP), cefoxitin (FOX), ertapenem (ETP), ciprofloxacin (CIP), gentamicin (GM), and trimethoprim/sulfamethoxazole (TMP-SMX). All of the isolates were tested by broth microdilution method for imipenem (IPM), azithromycin (AZM), amikacin (AMK), kanamycin (KAN), tetracycline (TET), chloramphenicol (CHL), and colistin (CL) and disc diffusion method was used for streptomycin (STR) on all isolates. All methodologies were performed according to the Clinical and Laboratory Standards Institute (CLSI) protocol \[[@pone.0216747.ref014], [@pone.0216747.ref015]\]. Antimicrobial agents used for broth microdilution were AMP, CFZ, FOX, CRO, CAZ, ETP, CIP, AZM, GM, AMK, KAN, TMP-SMX, TET, CHL, CL (all from Sigma-Aldrich, St. Louis, MO, USA), ATM, IPM, sulbactam (all from AdooQ Bioscience, Irvine, CA, USA) and FEP (Alfa Aesar, Tewksbury, MA, USA). In brief for broth microdilution, antimicrobial agents were 2-fold serially diluted in cation-adjusted Mueller Hinton broth (CAMHB, BBL Mueller Hinton II Broth, Becton Dickinson, Sparks, MD, USA) and 100 μl of each dilution including no-antibiotic control media were dispensed into 96 well round bottom culture plates. Bacterial suspensions were prepared in normal saline and adjusted to 0.5 McFarland standards following diluting at 1:20 in sterile distilled water to obtain 5 x 10^6^ cfu/ml. Then 10 μl of bacterial inoculum was inoculated into 96 well round bottom plates and incubated at 35 ± 2°C for 16--20 hour. Antimicrobial agents used for disc diffusion were AMP (10 μg), SAM (10/10 μg), CFZ (30 μg), FOX (30 μg), CRO (30 μg), CAZ (30 μg), FEP (30 μg), ATM (30 μg), ETP (10 μg), CIP (5 μg), GM (10 μg), STR (10 μg), and TMP-SMX (1.25/23.75 μg) (all from Becton Dickinson). For disc diffusion, the 0.5 McFarland standard bacterial suspensions were dipped by sterile cotton swab and swabs were streaked over the entire Mueller Hinton agar (MHA, BBL Mueller Hinton II Agar, Becton Dickinson) surface. The disc containing antibiotics were placed onto the surface of inoculated agar plate, and incubated at 35 ± 2°C for 16--18 hour. The *E*. *coli* ATCC 25922, and *P*. *aeruginosa* ATCC 27853 (for carbapenem) were used as quality control and the minimal inhibitory concentration (MIC) and zone diameter interpretative standard of CLSI-M100 Ed29 \[[@pone.0216747.ref016]\] were used for interpretation. The results of standard phenotypic AST and genotypic PCR testing were unblinded to the reader. If there were any discrepancies between PCR and AST then both methods were repeated and the repeat results were considered final (540/568 or 95.1% were identical to the original result). The phenotypic AST results of all isolates are shown in [S6 Table](#pone.0216747.s006){ref-type="supplementary-material"}.

Statistical analysis {#sec011}
--------------------

The sensitivity, specificity, and accuracy of genotypic test methods were analyzed against phenotypic methods as the gold standard. The kappa coefficient (κ) was calculated with GraphPad QuickCalcs (<https://www.graphpad.com/quickcalcs/kappa1.cfm>) to measure agreement between methods. Receiver-operating characteristic (ROC) analysis was performed with SPSS Statistics Software to define a Ct (quantification cycle) cut-off that optimized sensitivity and specificity.

Results {#sec012}
=======

Antimicrobial resistance associated gene targets {#sec013}
------------------------------------------------

We sought to develop assays to detect resistance to the antimicrobial classes commonly used in both human and veterinary medicine, namely penicillins, cephalosporins, carbapenems, fluoroquinolones, macrolides, aminoglycosides, folate pathway inhibitors, tetracyclines, phenicols, and polymyxins. The gene targets were chosen based on previously reported genes or mutations and we prioritized candidates based on global prevalence ([S7 Table](#pone.0216747.s007){ref-type="supplementary-material"}). Because there are many subgroups of genes (e.g., CTX-M), most assays were designed in conserved regions as group-specific assays ([S8 Table](#pone.0216747.s008){ref-type="supplementary-material"}). In addition to AMR targets, since a goal was to later evaluate these assays directly on stool specimens we also included *E*. *coli*/*Shigella* spp., *Salmonella* spp., and *Campylobacter* spp. specific assays for fluoroquinolone (in *gyrA* and *parC*) and macrolide resistance (in 23S rRNA), as well as previously published detection assays for these genera \[[@pone.0216747.ref017]--[@pone.0216747.ref020]\]. Additionally, internal and external controls were included (bacterial 16S rRNA and phocine herpesvirus, respectively). This amounted to PCR assays that included 69 primer pairs and 85 specific probes ([S4 Table](#pone.0216747.s004){ref-type="supplementary-material"}).

PCR assay performance versus sequencing {#sec014}
---------------------------------------

We organized the assays into 42 duplex reactions and 1 singleplex reaction on a 384 well plate using dilutions of positive control plasmid. The overall linearity of the 85 assays was 0.999 ± 0.002 and PCR efficiencies were 96.2% ± 3.9 ([S9 Table](#pone.0216747.s009){ref-type="supplementary-material"}). The specificity of the assays was tested against 15 other commonly found enteropathogens including *Aeromonas hydrophila*, *Adenovirus*, *Bacteroides fragilis*, *Blastocystis hominis*, *Clostridium difficile*, *Cryptosporidium hominis*, *Entamoeba histolytica*, *Encephalitozoon intestinalis*, *Giardia lamblia*, *Helicobacter pylori*, *Schistosoma mansoni*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Yersinia enterocolitica*, and *Yersinia pseudotuberculosis* and no false positives were observed. Assay performance was then tested against 236 previously-sequenced bacterial isolates consisting of several genera and species ([S1 Table](#pone.0216747.s001){ref-type="supplementary-material"}). The genotypic PCR assays showed 100% sensitivity and \>99.9% overall concordance against sequencing, with 11/20060 discrepancies ([Table 1](#pone.0216747.t001){ref-type="table"}).

10.1371/journal.pone.0216747.t001

###### Comparison of AMR-PCR assays versus sequencing on bacterial isolates (N = 236).

![](pone.0216747.t001){#pone.0216747.t001g}

  Targets                                              No of positive[^a^](#t001fn001){ref-type="table-fn"} tested   No of negative[^a^](#t001fn001){ref-type="table-fn"} tested   PCR assay result   Concordance (%)   Targets   No of positive[^a^](#t001fn001){ref-type="table-fn"} tested   No of negative[^a^](#t001fn001){ref-type="table-fn"} tested   PCR assay result   Concordance (%)             
  ---------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------ ----------------- --------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------ ----------------- --------- -----
  [Beta lactam genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                   
  TEM 104E                                             105                                                           131                                                           105                131               100       TEM 104K                                                      3                                                             233                3                 233       100
  TEM 164R                                             106                                                           130                                                           106                130               100       TEM 164SC                                                     2                                                             234                2                 234       100
  DHA                                                  3                                                             233                                                           3                  233               100       TEM 238S                                                      5                                                             231                5                 231       100
  SHV                                                  68                                                            168                                                           68                 167/168           99        SHV 238-240SE-SK                                              28                                                            208                28                208       100
  CTX-M1                                               43                                                            193                                                           43                 193               100       CTX-M8-M25                                                    0                                                             236                0                 236       100
  CTX-M2-M74                                           5                                                             231                                                           5                  231               100       CTX-M9                                                        6                                                             230                6                 229/230   99
  PER                                                  3                                                             233                                                           3                  233               100       VEB                                                           1                                                             235                1                 235       100
  CMY1-MOX                                             0                                                             236                                                           0                  236               100       FOX                                                           0                                                             236                0                 236       100
  CMY2-LAT                                             37                                                            199                                                           37                 199               100       ACT-MIR                                                       14                                                            222                14                222       100
  KPC                                                  37                                                            199                                                           37                 199               100       GES                                                           0                                                             236                0                 236       100
  NDM                                                  37                                                            199                                                           37                 199               100       VIM                                                           10                                                            226                10                226       100
  IMP                                                  5                                                             231                                                           5                  231               100       OXA-48                                                        12                                                            224                12                224       100
  OXA-1                                                37                                                            199                                                           37                 199               100       OXA-9                                                         30                                                            206                30                205/206   99
  [Fluoroquinolone genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                               
  QnrA                                                 3                                                             233                                                           3                  233               100       QnrS                                                          8                                                             228                8                 228       100
  QnrB1                                                17                                                            219                                                           17                 218/219           99        QnrB4                                                         20                                                            216                20                216       100
  aac(6')-lb-104W                                      68                                                            168                                                           68                 168               100       aac(6')-lb-104R                                               38                                                            198                38                198       100
  gyrA87G-ESh[^b^](#t001fn002){ref-type="table-fn"}    0                                                             236                                                           0                  236               100       aac(6')-lb-181Y                                               38                                                            198                38                198       100
  QepA                                                 1                                                             235                                                           1                  235               100       gyrA87G-Sal[^c^](#t001fn003){ref-type="table-fn"}             2                                                             234                2                 234       100
  gyrA83S-Sal[^c^](#t001fn003){ref-type="table-fn"}    8                                                             228                                                           8                  226/228           99        gyrA83FY-Sal[^c^](#t001fn003){ref-type="table-fn"}            3                                                             233                3                 233       100
  gyrA87D-Sal[^c^](#t001fn003){ref-type="table-fn"}    9                                                             227                                                           9                  227               100       gyrA87NY-Sal[^c^](#t001fn003){ref-type="table-fn"}            0                                                             236                0                 236       100
  gyrA83S-ESh[^b^](#t001fn002){ref-type="table-fn"}    22                                                            214                                                           22                 21                100       gyrA83L-ESh[^b^](#t001fn002){ref-type="table-fn"}             40                                                            196                40                195/196   99
  gyrA87D-ESh[^b^](#t001fn002){ref-type="table-fn"}    23                                                            213                                                           23                 213               100       gyrA87NY-ESh[^b^](#t001fn002){ref-type="table-fn"}            39                                                            197                39                197       100
  parC80S-Sal[^c^](#t001fn003){ref-type="table-fn"}    9                                                             227                                                           9                  226/227           99        parC80I-Sal[^c^](#t001fn003){ref-type="table-fn"}             2                                                             234                2                 234       100
  parC80S-ESh[^b^](#t001fn002){ref-type="table-fn"}    25                                                            211                                                           25                 211               100       parC80I-ESh[^b^](#t001fn002){ref-type="table-fn"}             37                                                            199                37                199       100
  gyrA86T-Cj[^d^](#t001fn004){ref-type="table-fn"}     3                                                             233                                                           3                  233               100       gyrA86I-Cj[^d^](#t001fn004){ref-type="table-fn"}              2                                                             234                2                 234       100
  gyrA86T-Cc[^e^](#t001fn005){ref-type="table-fn"}     3                                                             233                                                           3                  233               100       gyrA86I-Cc[^e^](#t001fn005){ref-type="table-fn"}              2                                                             234                2                 234       100
  [Macrolide genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                     
  23S-2075A-Cp[^f^](#t001fn006){ref-type="table-fn"}   5                                                             231                                                           5                  231               100       23S-2075G-Cp[^f^](#t001fn006){ref-type="table-fn"}            5                                                             231                5                 231       100
  ErmB                                                 6                                                             230                                                           6                  230               100       mphA                                                          50                                                            186                50                186       100
  [Aminoglycoside genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                
  armA                                                 17                                                            219                                                           17                 219               100       rmtB                                                          3                                                             233                3                 233       100
  aacC1                                                4                                                             232                                                           4                  232               100       aacC2                                                         52                                                            184                52                184       100
  aacC4                                                7                                                             229                                                           7                  229               100       aadB                                                          21                                                            215                21                215       100
  aphA1                                                38                                                            198                                                           38                 197/198           99        aadA1-2-17                                                    93                                                            143                93                143       100
  [Folate pathway inhibitor genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                      
  dfrA1                                                32                                                            204                                                           32                 204               100       dfrA12                                                        40                                                            196                40                196       100
  dfrA5-14                                             38                                                            198                                                           38                 198               100       dfrA17                                                        22                                                            214                22                212/214   99
  sul1                                                 125                                                           111                                                           125                111               100       sul2                                                          80                                                            156                80                156       100
  sul3                                                 8                                                             228                                                           8                  228               100                                                                                                                                                                                  
  [Tetracycline genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                  
  tetA                                                 58                                                            178                                                           58                 178               100       tetB                                                          25                                                            211                25                211       100
  [Phenicol genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                      
  catA1                                                39                                                            197                                                           39                 197               100       catB3                                                         8                                                             228                8                 228       100
  cmlA                                                 27                                                            209                                                           27                 209               100       floR                                                          18                                                            218                18                218       100
  [Polymyxin genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                     
  mcr-1                                                6                                                             230                                                           6                  230               100       mcr-2                                                         0                                                             236                0                 236       100
  [Bacterial genera and controls]{.ul}                                                                                                                                                                                                                                                                                                                                                                       
  *E*.*coli-Shigella*                                  61                                                            175                                                           61                 175               100       *Shigella* spp.                                               7                                                             229                7                 229       100
  *Salmonella* spp.                                    11                                                            225                                                           11                 225               100       *C*. *jejuni-coli*                                            10                                                            226                10                226       100
  PhHV                                                 0                                                             236                                                           0                  236               100       Bacterial 16S                                                 236                                                           0                  236               0         100
  Total                                                2171                                                          17889                                                         2171               17878/17889       99.9                                                                                                                                                                                 

^a^ Whole genome sequencing or Sanger sequencing

^b^ ESh; *E*.*coli-Shigella* spp.,

^c^ Sal; *Salmonella* spp.,

^d^ Cj; *C*. *jejuni*,

^e^ Cc; *C*. *coli*,

^f^ Cp; *Campylobacter* spp.

Note: isolates that had both mutation and wild-type *gyrA* and/or *parC* were excluded from analysis of fluoroquinolone resistance.

Correlation between genotypic and phenotypic antimicrobial susceptibility testing {#sec015}
---------------------------------------------------------------------------------

We then evaluated the correlation between genotypic and phenotypic AST on 239 *E*.*coli* isolates. This included a range of susceptible and resistant isolates from FDA-CDC-AR bank (n = 42), ARLG (n = 4), ATCC (n = 5), clinical human isolates (n = 81) and swine isolates (n = 107). This evaluation is based on the necessary but oversimplified assumption that if a resistance-associated gene or mutation was present, at any quantity (Ct cutoff 30), then that isolate would be resistant to that antimicrobial agent, while if such a gene or mutation was absent then the isolate would be susceptible. This comparison showed that the sensitivity for detecting phenotypic resistance ranged between 86% - 100% for 15 antimicrobial agents (i.e., the very major error rates were 0--14%), whereas sensitivity for resistance to cefoxitin, kanamycin, streptomycin, colistin, and ampicillin/sulbactam was lower at 76%, 75%, 72%, 67%, and 43% respectively ([Table 2](#pone.0216747.t002){ref-type="table"}). The specificity of the assays for detecting phenotypic susceptibility ranged between 88% - 100% for all antimicrobial agents (i.e., major error rates 0--12%) except streptomycin and cefazolin (78% and 70%, respectively). Overall, sensitivity and specificity exceeded 90% for ampicillin, ceftriaxone, cefepime, imipenem, ciprofloxacin, azithromycin, gentamicin, amikacin, trimethoprim/sulfamethoxazole, tetracycline, and chloramphenicol phenotypic susceptibility results, with substantial or better kappa (κ) agreement between the two methods (κ = 0.79--0.97). Categorical agreement of the genotypic versus phenotypic method, ignoring intermediate results which cannot be categorized, was greater than 90% for all antimicrobial agents except for ampicillin/sulbactam (66%) and streptomycin (74%).

10.1371/journal.pone.0216747.t002

###### Correlation between genotypic (AMR-PCR assay) and phenotypic AST of *E*. *coli* isolates (N = 239).

![](pone.0216747.t002){#pone.0216747.t002g}

  Antibiotic                                            Resistant genes                                                        PCR assay   Phenotypic AST[^a^](#t002fn001){ref-type="table-fn"}   Sens. (%)   Spec. (%)   Categorical agreement (%)   Kappa[^b^](#t002fn002){ref-type="table-fn"} (κ)        
  ----------------------------------------------------- ---------------------------------------------------------------------- ----------- ------------------------------------------------------ ----------- ----------- --------------------------- ------------------------------------------------- ---- ------
  Ampicillin                                            Class A β-lactamase; TEM, SHV, CTX-M1, CTX-M8, CTX-M9, KPC             Positive    202                                                    1           1           99                          97                                                99   0.97
                                                        Class B β-lactamase; NDM                                               Negative    1                                                      1           33                                                                                             
                                                        Class C β-lactamase; CMY2-LAT, ACT-MIR, DHA                                                                                                                                                                                                          
                                                        Class D β-lactamase; OXA-1, OXA-9, OXA-48                                                                                                                                                                                                            
  Ampicillin/                                           Class B β-lactamase; NDM                                               Positive    45                                                     8           0           43                          100                                               66   0.38
  sulbactam                                             Class C β-lactamase; CMY2-LAT, ACT-MIR, DHA                            Negative    59                                                     55          72                                                                                             
                                                        Class D β-lactamase; OXA-1, OXA-9, OXA-48                                                                                                                                                                                                            
  Cefazolin                                             Class A β-lactamase; TEM, SHV, CTX-M1, CTX-M8, CTX-M9, KPC             Positive    137                                                    53          14          99                          70                                                91   0.75
                                                        Class B β-lactamase; NDM                                               Negative    2                                                      0           33                                                                                             
                                                        Class C β-lactamase; CMY2-LAT, ACT-MIR, DHA                                                                                                                                                                                                          
                                                        Class D β-lactamase; OXA-1, OXA-9, OXA-48                                                                                                                                                                                                            
  Cefoxitin                                             Class B β-lactamase; NDM                                               Positive    31                                                     2           0           76                          100                                               96   0.84
                                                        Class C β-lactamase; CMY2-LAT, ACT-MIR, DHA                            Negative    10                                                     13          183                                                                                            
  Ceftazidime                                           Class A β-lactamase; TEM-ESBL, SHV-ESBL, CTX-M1, CTX-M8, CTX-M9, KPC   Positive    71                                                     6           19          100                         88                                                92   0.82
                                                        Class B β-lactamase; NDM                                               Negative    0                                                      0           143                                                                                            
                                                        Class C β-lactamase; CMY2-LAT, ACT-MIR, DHA                                                                                                                                                                                                          
  Ceftriaxone                                           Class A β-lactamase; TEM-ESBL, SHV-ESBL, CTX-M1, CTX-M8, CTX-M9, KPC   Positive    87                                                     0           7           99                          95                                                97   0.93
                                                        Class B β-lactamase; NDM                                               Negative    1                                                      0           144                                                                                            
                                                        Class C β-lactamase; CMY2-LAT, ACT-MIR, DHA                                                                                                                                                                                                          
  Cefepime                                              Class A β-lactamase; CTX-M1, CTX-M8, CTX-M9, KPC                       Positive    58                                                     9           8           95                          95                                                95   0.88
                                                        Class B β-lactamase; NDM                                               Negative    3                                                      1           160                                                                                            
  Aztreonam                                             Class A β-lactamase; TEM-ESBL, SHV-ESBL, CTX-M1, CTX-M8, CTX-M9, KPC   Positive    69                                                     5           20          100                         88                                                91   0.81
                                                        Class C β-lactamase; CMY2-LAT, ACT-MIR, DHA                            Negative    0                                                      1           144                                                                                            
  Ertapenem                                             Class A β-lactamase; KPC                                               Positive    18                                                     0           0           86                          100                                               99   0.92
                                                        Class B β-lactamase; NDM                                               Negative    3                                                      2           216                                                                                            
                                                        Class D β-lactamase; OXA-48                                                                                                                                                                                                                          
  Imipenem                                              Class A β-lactamase; KPC                                               Positive    18                                                     0           0           90                          100                                               99   0.94
                                                        Class B β-lactamase; NDM                                               Negative    2                                                      0           219                                                                                            
                                                        Class D β-lactamase; OXA-48                                                                                                                                                                                                                          
  Ciprofloxacin[^c^](#t002fn003){ref-type="table-fn"}   gyrA, parC                                                             Mutant      61                                                     0           7           97                          94                                                95   0.89
                                                                                                                               Mt + Wt     17                                                     6           12                                                                                             
                                                                                                                               Wild-type   2                                                      17          117                                                                                            
  Azithromycin[^d^](#t002fn004){ref-type="table-fn"}    ermB, mphA                                                             Positive    78                                                     0           3           95                          98                                                97   0.93
                                                                                                                               Negative    4                                                      0           154                                                                                            
  Gentamicin                                            aacC2, aacC4, aac(6')-lb, aadB, rmtB                                   Positive    79                                                     1           4           96                          97                                                97   0.93
                                                                                                                               Negative    3                                                      0           152                                                                                            
  Amikacin                                              aac(6')-lb, rmtB                                                       Positive    12                                                     0           6           100                         97                                                97   0.79
                                                                                                                               Negative    0                                                      0           221                                                                                            
  Kanamycin                                             aphA1                                                                  Positive    51                                                     1           0           75                          100                                               93   0.81
                                                                                                                               Negative    17                                                     2           168                                                                                            
  Streptomycin                                          aadA1-2-17                                                             Positive    107                                                    9           18          72                          78                                                74   0.47
                                                                                                                               Negative    41                                                     1           63                                                                                             
  Trimethoprim/                                         dfrA1, dfrA5-14, dfrA12, dfrA17, sul1, sul2, sul3                      Positive    168                                                    0           2           92                          96                                                93   0.83
  sulfamethoxazole                                                                                                             Negative    14                                                     0           55                                                                                             
  Tetracycline                                          tetA, tetB                                                             Positive    172                                                    0           4           99                          94                                                97   0.94
                                                                                                                               Negative    2                                                      0           61                                                                                             
  Chloramphenicol                                       catA1, catB3, cmlA, floR                                               Positive    112                                                    6           9           99                          92                                                96   0.91
                                                                                                                               Negative    1                                                      9           102                                                                                            
  Colistin[^e^](#t002fn005){ref-type="table-fn"}        mcr-1                                                                  Positive    29                                                     0           1           67                          99                                                94   0.76
                                                                                                                               Negative    14                                                     0           195                                                                                            

^a^ Excluded intermediate (I) from analysis

^b^ Strength of the kappa (κ) coefficients: 0.01--0.20 slight; 0.21--0.40 fair; 0.41--0.60 moderate; 0.61--0.80 substantial; 0.81--1.0 almost perfect agreement

^c^ Excluded 35 mixed mutant and wild-type from analysis

^d^ Used interpretative criteria of CLSI M100 29Ed \[[@pone.0216747.ref016]\] for *Salmonella enterica* Typhi where MIC ≤16 is susceptible and ≥32 is resistant

^e^ Used interpretative criteria of CLSI M100 29Ed \[[@pone.0216747.ref016]\] for *Pseudomonas aeruginosa* where MIC ≤2 is susceptible and ≥4 is resistant

Sens.; sensitivity, Spec.; specificity

AMR detection in direct stool specimens {#sec016}
---------------------------------------

We then sought to evaluate the sensitivity of these AMR-PCR assays on direct stool specimens versus the genotypic pattern of the *E*. *coli* cultured from the stool. The focus on *E*. *coli* was based on its importance as an indicator organism, a member of the stool microbiome, and a reservoir of AMR genes. Comparing results from 220 stool DNA (70 human, 150 swine) versus the paired *E*.*coli* isolates cultured from those stools, using a Ct cut-off of 32 ([S1 Fig](#pone.0216747.s011){ref-type="supplementary-material"} for ROC analysis), direct genotypic testing of stool predicted the cultured *E*. *coli* genotype with an overall sensitivity of 97% ± 5 across all genes, an overall specificity of 75% ± 31, and an overall accuracy 85% ± 17 ([Table 3](#pone.0216747.t003){ref-type="table"}).

10.1371/journal.pone.0216747.t003

###### Comparison of AMR-PCR assay detection in direct stool and paired *E*.*coli* isolates (N = 220).

![](pone.0216747.t003){#pone.0216747.t003g}

  Targets                                             N positive by culture[^a^](#t003fn001){ref-type="table-fn"}   N negative by culture[^a^](#t003fn001){ref-type="table-fn"}   Direct stool result   Sens. (%)   Spec. (%)   Targets   N positive by culture[^a^](#t003fn001){ref-type="table-fn"}   N negative by culture[^a^](#t003fn001){ref-type="table-fn"}   Direct stool result   Sens. (%)   Spec. (%)         
  --------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- --------------------- ----------- ----------- --------- ------------------------------------------------------------- ------------------------------------------------------------- --------------------- ----------- ----------- ----- -----
  [Beta lactam genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                
  TEM 104E                                            190                                                           30                                                            190                   0/30        100         0         TEM 104K                                                      0                                                             220                   0           220         NA    100
  TEM 164R                                            190                                                           30                                                            190                   0/30        100         0         TEM 164SC                                                     0                                                             220                   0           220         NA    100
  DHA                                                 2                                                             218                                                           2                     183/218     100         84        TEM 238S                                                      0                                                             220                   0           220         NA    100
  SHV                                                 2                                                             218                                                           2                     181/218     100         83        SHV 238-240SE-SK                                              0                                                             220                   0           205/220     NA    93
  CTX-M1                                              42                                                            178                                                           40/42                 143/178     95          80        CTX-M8-M25                                                    1                                                             219                   1           211/219     100   96
  CTX-M2-M74                                          0                                                             220                                                           0                     218/220     NA          99        CTX-M9                                                        29                                                            191                   27/29       139/191     93    73
  PER                                                 0                                                             220                                                           0                     218/220     NA          99        VEB                                                           2                                                             218                   2           151/218     100   69
  CMY1-MOX                                            0                                                             220                                                           0                     217/220     NA          99        FOX                                                           0                                                             220                   0           220/220     NA    100
  CMY2-LAT                                            8                                                             212                                                           7/8                   170/212     87          80        ACT-MIR                                                       4                                                             216                   4           178/216     100   82
  KPC                                                 0                                                             220                                                           0                     220/220     NA          100       GES                                                           0                                                             220                   0           196/220     NA    89
  NDM                                                 0                                                             220                                                           0                     220/220     NA          100       VIM                                                           0                                                             220                   0           220         NA    100
  IMP                                                 0                                                             220                                                           0                     216/220     NA          98        OXA-48                                                        0                                                             220                   0           220         NA    100
  OXA-1                                               14                                                            206                                                           11/14                 138/206     79          67        OXA-9                                                         0                                                             220                   0           220         NA    100
  [Fluoroquinolone genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                            
  QnrA                                                0                                                             220                                                           0                     218/220     NA          99        QnrS                                                          126                                                           94                    126         54/94       100   57
  QnrB1                                               0                                                             220                                                           0                     175/220     NA          79        QnrB4                                                         1                                                             219                   1           211/219     100   96
  aac(6')-lb-104W                                     3                                                             217                                                           3                     141/217     100         65        aac(6')-lb-104R                                               4                                                             216                   4           197/216     100   91
  gyrA87G-ESh[^b^](#t003fn002){ref-type="table-fn"}   2                                                             218                                                           2                     217/218     100         99        aac(6')-lb-181Y                                               4                                                             216                   4           192/216     100   89
  gyrA83S-ESh[^b^](#t003fn002){ref-type="table-fn"}   196                                                           24                                                            195/196               20/24       99          83        gyrA83L-ESh[^b^](#t003fn002){ref-type="table-fn"}             86                                                            134                   77/86       124/134     89    92
  gyrA87D-ESh[^b^](#t003fn002){ref-type="table-fn"}   206                                                           14                                                            206                   12/14       100         86        gyrA87NY-ESh[^b^](#t003fn002){ref-type="table-fn"}            37                                                            183                   33/37       180/183     89    98
  parC80S-ESh[^b^](#t003fn002){ref-type="table-fn"}   199                                                           21                                                            197/199               19/21       99          90        parC80I-ESh[^b^](#t003fn002){ref-type="table-fn"}             30                                                            190                   28/30       188/190     93    99
  QepA                                                1                                                             219                                                           1                     214/219     100         98                                                                                                                                                                                        
  [Macrolide genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                  
  ermB                                                39                                                            181                                                           39                    57/181      100         31        mphA                                                          70                                                            150                   67/70       92/150      96    61
  [Aminoglycoside genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                             
  armA                                                0                                                             220                                                           0                     220         NA          100       rmtB                                                          5                                                             215                   5           205/215     100   95
  aacC1                                               0                                                             220                                                           0                     204/220     NA          93        aacC2                                                         95                                                            125                   93/95       81/125      98    65
  aacC4                                               7                                                             213                                                           7                     72/213      100         34        aadB                                                          5                                                             215                   5           87/215      100   40
  aphA1                                               80                                                            140                                                           80                    43/140      100         31        aadA1-2-17                                                    172                                                           48                    171/172     7/48        99    15
  [Folate pathway inhibitor genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                   
  dfrA1                                               43                                                            177                                                           43                    23/177      100         13        dfrA12                                                        137                                                           83                    136/137     52/83       99    63
  dfrA5-14                                            82                                                            138                                                           78/82                 80/138      95          58        dfrA17                                                        46                                                            174                   36/46       138/174     78    79
  sul1                                                73                                                            147                                                           73                    14/147      100         9         sul2                                                          154                                                           66                    154         0/66        100   0
  sul3                                                145                                                           75                                                            142/145               65/75       98          87                                                                                                                                                                                  100   NA
  [Tetracycline genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                               
  tetA                                                177                                                           43                                                            176/177               1/43        99          2         tetB                                                          108                                                           112                   108         15/112      100   13
  [Phenicol genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                   
  catA1                                               44                                                            176                                                           41/44                 148/176     93          84        catB3                                                         3                                                             217                   3/3         173/217     100   80
  cmlA                                                143                                                           77                                                            141/143               68/77       99          88        floR                                                          72                                                            148                   71/72       123/148     99    83
  [Polymyxin genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                                                  
  mcr-1                                               26                                                            194                                                           26                    176/194     100         91        mcr-2                                                         0                                                             220                   0           192/220     NA    87
  [Bacterial genera and control]{.ul}                                                                                                                                                                                                                                                                                                                                                                                     
  *E*.*coli-Shigella*                                 220                                                           0                                                             220                   0           100         NA        *Shigella* spp.                                               0                                                             220                   0           220/220     NA    100
  Bacterial 16S                                       220                                                           0                                                             220                   0           100         NA                                                                                                                                                                                        

^a^ *E*. *coli* isolated from paired stool samples

^b^ ESh; *E*.*coli-Shigella* spp.

NA; not applicable, Sens.; sensitivity, Spec.; specificity

Performance of AMR-TAC {#sec017}
----------------------

The AMR-PCR assays were then compartmentalized into a TaqMan array card (TAC) format and the analytical PCR performance of each assay was determined ([Fig 1](#pone.0216747.g001){ref-type="fig"}). The overall linearity of the 85 targets was 0.999 ± 0.001 and PCR efficiencies were 95.1% ± 2.5 ([S10 Table](#pone.0216747.s010){ref-type="supplementary-material"}). The limit of detection, defined as lowest copy number that was detected in all 10 extractions/amplification, was 10^4^ copies per 200 mg stool (10 copies per PCR reaction). The coefficient of variant (CV) of Ct values was 3.6% ± 2.0 and 4.7% ± 2.1 for repeatability and reproducibility, respectively. The performance of AMR-TAC was then determined against 122 DNA samples including direct stools (n = 56) and cultured isolates (n = 66). TAC yielded nearly perfect concordance with the plate results: 100% concordance on cultured isolates and 99.6% ± 1.5 sensitivity and 99.2% ± 3.5 specificity on direct stools ([Table 4](#pone.0216747.t004){ref-type="table"}).

![Antimicrobial resistance TaqMan array card (AMR-TAC) layout.\
The TaqMan array card includes 8 sample ports. Each well was configured and grouped according to antimicrobial resistance associated with those gene targets. Two wells were used for bacterial species/genera detection. The symbol "/" indicates a duplex assay. Because we amplified 42 duplex, 1 singleplex (DHA), and 1 singleplex manufacturing control target, only 44 wells were used out of the 48 well TAC card.](pone.0216747.g001){#pone.0216747.g001}

10.1371/journal.pone.0216747.t004

###### Performance of TaqMan array card (TAC) compared with 384 well PCR plate for AMR detection in direct stool and cultured isolates (N = 122).

![](pone.0216747.t004){#pone.0216747.t004g}

  Targets                                              N positive[^a^](#t004fn001){ref-type="table-fn"} tested   N negative[^a^](#t004fn001){ref-type="table-fn"} tested   TAC result   Sens. (%)   Spec. (%)   Targets   N positive[^a^](#t004fn001){ref-type="table-fn"} tested   N negative[^a^](#t004fn001){ref-type="table-fn"} tested   TAC result   Sens. (%)   Spec. (%)         
  ---------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ------------ ----------- ----------- --------- --------------------------------------------------------- --------------------------------------------------------- ------------ ----------- ----------- ----- -----
  [Beta lactam genes]{.ul}                                                                                                                                                                                                                                                                                                                                                               
  TEM 104E                                             97                                                        25                                                        97           25          100         100       TEM 104K                                                  3                                                         119          3           119         100   100
  TEM 164R                                             98                                                        24                                                        98           24          100         100       TEM 164SC                                                 3                                                         119          3           119         100   100
  DHA                                                  18                                                        104                                                       17/18        103/104     94          99        TEM 238S                                                  3                                                         119          3           119         100   100
  SHV                                                  44                                                        78                                                        44           78          100         100       SHV238-240SE-SK                                           21                                                        101          20/21       101         95    100
  CTX-M1                                               51                                                        71                                                        50/51        70/71       98          99        CTX-M8-M25                                                15                                                        107          15          106/107     100   99
  CTX-M2-M74                                           6                                                         116                                                       6            116         100         100       CTX-M9                                                    39                                                        83           39          83          100   100
  PER                                                  5                                                         117                                                       5            117         100         100       VEB                                                       28                                                        94           28          94          100   100
  CMY1-MOX                                             3                                                         119                                                       3            119         100         100       FOX                                                       0                                                         122          0           122         NA    100
  CMY2-LAT                                             39                                                        83                                                        39           83          100         100       ACT-MIR                                                   26                                                        96           26          96          100   100
  KPC                                                  5                                                         117                                                       5            117         100         100       GES                                                       19                                                        103          19          103         100   100
  NDM                                                  11                                                        111                                                       11           111         100         100       VIM                                                       3                                                         119          3           119         100   100
  IMP                                                  9                                                         113                                                       9            112/113     100         99        OXA-48                                                    3                                                         119          3           119         100   100
  OXA-1                                                42                                                        80                                                        42           80          100         100       OXA-9                                                     10                                                        112          10          112         100   100
  [Fluoroquinolone genes]{.ul}                                                                                                                                                                                                                                                                                                                                                           
  QnrA                                                 5                                                         117                                                       5            117         100         100       QnrS                                                      52                                                        70           52          70          100   100
  QnrB1                                                32                                                        90                                                        32           90          100         100       QnrB4                                                     19                                                        103          19          103         100   100
  aac(6')-lb-104W                                      52                                                        70                                                        52           69/70       100         99        aac(6')-lb-104R                                           30                                                        92           30          92          100   100
  gyrA87G-ESh[^b^](#t004fn002){ref-type="table-fn"}    1                                                         121                                                       1            121         100         100       aac(6')-lb-181Y                                           28                                                        94           28          94          100   100
  QepA                                                 8                                                         114                                                       8            114         100         100       gyrA87G-Sal[^c^](#t004fn003){ref-type="table-fn"}         2                                                         120          2           120         100   100
  gyrA83S-Sal[^c^](#t004fn003){ref-type="table-fn"}    4                                                         118                                                       4            118         100         100       gyrA83FY-Sal[^c^](#t004fn003){ref-type="table-fn"}        3                                                         119          3           119         100   100
  gyrA87D-Sal[^c^](#t004fn003){ref-type="table-fn"}    4                                                         118                                                       4            118         100         100       gyrA87NY-Sal[^c^](#t004fn003){ref-type="table-fn"}        0                                                         122          0           122         NA    100
  gyrA83S-ESh[^b^](#t004fn002){ref-type="table-fn"}    58                                                        64                                                        58           64          100         100       gyrA83L-ESh[^b^](#t004fn002){ref-type="table-fn"}         57                                                        65           57          65          100   100
  gyrA87D-ESh[^b^](#t004fn002){ref-type="table-fn"}    61                                                        61                                                        61           61          100         100       gyrA87NY-ESh[^b^](#t004fn002){ref-type="table-fn"}        33                                                        89           33          89          100   100
  parC80S-Sal[^c^](#t004fn003){ref-type="table-fn"}    4                                                         118                                                       4            118         100         100       parC80I-Sal[^c^](#t004fn003){ref-type="table-fn"}         2                                                         120          2           120         100   100
  parC80S-ESh[^b^](#t004fn002){ref-type="table-fn"}    61                                                        61                                                        61           61          100         100       parC80I-ESh[^b^](#t004fn002){ref-type="table-fn"}         27                                                        95           27          95          100   100
  gyrA86T-Cj[^d^](#t004fn004){ref-type="table-fn"}     5                                                         117                                                       5            117         100         100       gyrA86I-Cj[^d^](#t004fn004){ref-type="table-fn"}          2                                                         120          2           120         100   100
  gyrA86T-Cc[^e^](#t004fn005){ref-type="table-fn"}     2                                                         120                                                       2            120         100         100       gyrA86I-Cc[^e^](#t004fn005){ref-type="table-fn"}          15                                                        107          15          107         100   100
  [Macrolide genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                 
  23S-2075A-Cp[^f^](#t004fn006){ref-type="table-fn"}   22                                                        100                                                       21/22        100         95          100       23S-2075G-Cp[^f^](#t004fn006){ref-type="table-fn"}        33                                                        89           33          89          100   100
  ermB                                                 50                                                        72                                                        50           72          100         100       mphA                                                      65                                                        57           65          57          100   100
  [Aminoglycoside genes]{.ul}                                                                                                                                                                                                                                                                                                                                                            
  armA                                                 6                                                         116                                                       6            116         100         100       rmtB                                                      13                                                        109          13          109         100   100
  aacC1                                                15                                                        107                                                       15           107         100         100       aacC2                                                     68                                                        54           68          54          100   100
  aacC4                                                41                                                        81                                                        41           80/81       100         99        aadB                                                      44                                                        78           44          78          100   100
  aphA1                                                62                                                        60                                                        62           60          100         100       aadA1-2-17                                                84                                                        38           83/84       38          99    100
  [Folate pathway inhibitor genes]{.ul}                                                                                                                                                                                                                                                                                                                                                  
  dfrA1                                                65                                                        57                                                        65           57          100         100       dfrA12                                                    61                                                        61           61          61          100   100
  dfrA5-14                                             60                                                        62                                                        60           60/62       100         97        dfrA17                                                    41                                                        81           41          77/81       100   95
  sul1                                                 95                                                        27                                                        95           27          100         100       sul2                                                      83                                                        39           83          39          100   100
  sul3                                                 50                                                        72                                                        50           72          100         100                                                                                                                                                                      
  [Tetracycline genes]{.ul}                                                                                                                                                                                                                                                                                                                                                              
  tetA                                                 76                                                        46                                                        76           46          100         100       tetB                                                      70                                                        52           70          52          100   100
  [Phenicol genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                  
  catA1                                                45                                                        77                                                        45           77          100         100       catB3                                                     28                                                        94           28          93/94       100   99
  cmlA                                                 58                                                        64                                                        58           64          100         100       floR                                                      52                                                        70           52          70          100   100
  [Polymyxin genes]{.ul}                                                                                                                                                                                                                                                                                                                                                                 
  mcr-1                                                30                                                        92                                                        30           92          100         100       mcr-2                                                     9                                                         113          9           113         100   100
  [Bacterial genera and controls]{.ul}                                                                                                                                                                                                                                                                                                                                                   
  *E*.*coli-Shigella*                                  81                                                        41                                                        81           41          100         100       *Shigella* spp.                                           5                                                         117          5           117         100   100
  *Salmonella* spp.                                    7                                                         115                                                       7            115         100         100       *C*. *jejuni-coli*                                        24                                                        98           24          98          100   100
  PhHV                                                 56                                                        66                                                        54/56        66          96          100       Bacterial 16S                                             122                                                       0            122         0           100   NA

^a^ Results on 384 well PCR plate

^b^ ESh; *E*.*coli-Shigella* spp.,

^c^ Sal; *Salmonella* spp.,

^d^ Cj; *C*. *jejuni*,

^e^Cc; *C*. *coli*,

^f^ Cp; *Campylobacter* spp.

NA; not applicable, Sens.; sensitivity, Spec.; specificity

Discussion {#sec018}
==========

In this work we developed an extensive menu of qPCR assays to detect AMR-associated genes or mutations for 10 antimicrobial classes that can be used for epidemiologic purposes. The accuracy was almost perfect compared to direct sequencing, with only 0.05% discrepancy. When used on direct stool samples, the PCR assays were sensitive at detecting the AMR genes carried by resident *E*. *coli*. As expected the specificity was lower, presumably because AMR genes in stool derive from any member of bacteria besides *E*. *coli*. Such a high sensitivity assay could be useful as a screening test of the resistome in surveillance specimens such as human and livestock stool or environmental materials for epidemiologic purposes \[[@pone.0216747.ref021], [@pone.0216747.ref022]\]. Of course, further evaluation in this area is needed, as mechanisms of resistance may differ geographically, and we only assessed stool specimens from two countries.

The genotypic-phenotypic correlation on bacterial isolates was good, yielding \>90% sensitivity and specificity versus the phenotypic results for ampicillin, ceftriaxone, cefepime, imipenem, ciprofloxacin, azithromycin, gentamicin, amikacin, trimethoprim/sulfamethoxazole, tetracycline, and chloramphenicol across a range of genera. Antimicrobial agents whose genotypic-phenotypic correlation was suboptimal included ampicllin/sulbactam, potentially because we included a limited number of class D β-lactamase (OXA-type) targets or because of other mechanisms of resistance, such as penicillinase hyperproduction, overproduction of constitutive AmpC cephalosporinase, and inhibitor-resistant TEM (IRT) β-lactamase \[[@pone.0216747.ref023]\]. Cefoxitin resistance was also difficult to detect genotypically (76% sensitivity), perhaps because we only included plasmid mediated AmpC β-lactamase, not chromosomal AmpC, or because we did not test for outer membrane porins \[[@pone.0216747.ref024], [@pone.0216747.ref025]\]. Similarly, for colistin (67% sensitivity) we only included the plasmid-mediated *mcr* gene, while resistance may be due to several other mechanisms \[[@pone.0216747.ref017]\]. Detecting kanamycin and streptomycin resistance was also of lower sensitivity, perhaps because other targets such as *aph(3')-IIa*, *strA*, and *strB* \[[@pone.0216747.ref026]\] were not included. As for the specificity to detect susceptibility, cefazolin was the lowest (70%) and mostly due to *bla*~TEM~ positive but phenotypically susceptible isolates, likely due to low expression. Results for streptomycin and *aadA* were similar. Therefore, if a phenotypic susceptibility result for these drugs is desired, further assay optimization is needed. These drugs aside, however, the assays worked are usable for surveillance purposes for the 11 drugs with \>90% sensitivity and specificity: ampicillin, ceftriaxone, cefepime, imipenem, ciprofloxacin, azithromycin, gentamicin, amikacin, trimethoprim/sulfamethoxazole, tetracycline, and chloramphenicol. Certainly, use for clinical care would require commercial development, and major error and very major error rates should be below 3% and 1.5% per CLSI.

If desired, the PCR assays can be used on the TaqMan Array Card format. We have found this to be an easy to perform, rapid, and high-throughput tool. Cost of the TAC reagents (\~\$50 per specimen) and platform remain a substantial limitation. However the alternatives are costly as well. Sanger sequencing is costly, as are whole genome sequencing technologies, which also requires extensive bioinformatic interpretation \[[@pone.0216747.ref027]--[@pone.0216747.ref029]\].

In sum, we present a menu of AMR qPCR assays that can be used for tracking AMR in bacterial isolates, primarily Enterobacteriaceae and *E*. *coli*, and also in direct stool specimens for epidemiologic purposes.
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